Viking Therapeutics Set to Showcase Innovations at Major Healthcare Conferences
Viking Therapeutics Set to Showcase Innovations at Major Healthcare Conferences
Viking Therapeutics, Inc. (NASDAQ: VKTX), a cutting-edge clinical-stage biopharmaceutical firm, has announced its participation in several upcoming investor conferences this November and December. As a company devoted to developing progressive therapies for metabolic and endocrine disorders, Viking aims to highlight its ongoing work, especially in obesity treatments.
Upcoming Conference Details
The investor conferences set to feature Viking Therapeutics include:
1. Stifel 2026 Healthcare Conference
- - Dates: November 10-12, 2026
- - Location: New York, NY
- - Focus: Viking management will engage in investor meetings alongside a featured fireside chat on November 11th from 10:40 am to 11:10 am ET.
2. Truist 2026 BioPharma Symposium
- - Date: November 12, 2026
- - Location: New York, NY
- - Details: Viking management will partake in discussions during investor meetings.
3. UBS Global Biopharma Conference
- - Dates: November 16-17, 2026
- - Location: London, UK
- - Details: Viking management will be part of a fireside chat on November 17th from 10:40 am to 11:10 am ET, along with investor meetings.
4. Jefferies Global Healthcare Conference
- - Dates: November 16-19, 2026
- - Location: London, UK
- - Details: A fireside chat is scheduled for November 18th from 2:00 pm to 2:25 pm GMT, alongside investor meetings, with a webcast available.
5. Piper Sandler 38th Annual Healthcare Conference
- - Dates: December 1-3, 2026
- - Location: New York, NY
- - Details: This will feature another fireside chat on December 2nd from 2:00 pm to 2:25 pm ET, and a webcast will also be provided.
Live webcasts for the Jefferies and Piper Sandler fireside chats will be accessible through the Viking Therapeutics website. Additionally, recordings of each session will be available for later viewing, ensuring prospective investors can catch up on the discussions.
About Viking Therapeutics
Founded with a mission to pioneer next-generation therapies for obesity and metabolic health, Viking Therapeutics stands out in the biopharmaceutical arena. Their flagship program, VK2735, is a dual GLP-1 and GIP receptor agonist currently in Phase 3 clinical trials aimed at obesity treatment. The company is also exploring various innovative strategies to support sustained weight management in individuals, demonstrating its commitment to holistic health solutions.
Apart from VK2735, Viking Therapeutics is advancing multiple other candidates such as VK3019, an amylin receptor agonist, and VK2809, which targets metabolic and liver disorders using an orally available thyroid hormone receptor beta agonist. The firm also has VK0214 in development for X-linked adrenoleukodystrophy, a rare genetic condition.
Viking Therapeutics' holistic approach, characterized by robust scientific research and a deep commitment to metabolic health, aims to create therapies that can significantly enhance the quality of life for those suffering from these disorders.
For further information about Viking Therapeutics and its innovative product pipeline, please visit www.vikingtherapeutics.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.